1. Kelsall A, Iqbal A, Newell-Price J. Adrenal incidentaloma:cardiovascular and metabolic effects of mild cortisol excess. GlandSurgery. 2020;9(1):94.
2. Komarowska H, Brominska B, Janicka-Jedynska M, Ruchala M.Adrenal incidentaloma: nothing is ever as it seems. Am J Med.2020;133(9):1048-1050.
3. Reimondo G, Muller A, Ingargiola E, Puglisi S, Terzolo M. Is follow-up of adrenal incidentalomas always mandatory? Endocrinol Metab.2020;35(1):26-35.
4. Akkuş O, Akkuş G, Kaypaklı O, et al. Increased rates of coronary arterycalcium score in patients with non-functioning adrenal incidentaloma.Endocrine Metab Immune Disord Drug Targ (Formerly Current DrugTargets-Immune, Endocrine & Metabolic Disorders). 2021;21(7):1319-1325.
5. Akkuş G, Evran M, Sert M, Tetiker T. Adipocytokines in non-functional adrenal incidentalomas and relation with insulin resistanceparameters. Endocrine Metab Immune Disord Drug Targ (FormerlyCurrent Drug Targets-Immune, Endocrine & Metabolic Disorders).2019:19(3):326-332.
6. Kim BJ, Kwak MK, Ahn SH, Kim JS, Lee SH, Koh JM. The associationof cortisol and adrenal androgen with trabecular bone score in patientswith adrenal incidentaloma with and without autonomous cortisolsecretion. Osteoporosis Int. 2018;29(10):2299-2307.
7. Altieri B, Muscogiuri G, Paschou SA, et al. Adrenocorticalincidentalomas and bone: from molecular insights to clinicalperspectives. Endocrine. 2018;62(3):506-516.
8. Morelli V, Donadio F, Eller-Vainicher C. Role of glucocorticoidreceptor polymorphism in adrenal incidentalomas. Eur J Clin Invest.2010;40(9):803-811.
9. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M,Stewart PM. Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1activity increases with age and glucocorticoid exposure. J Bone MinerRes. 2002;17(6): 979-986.
10. Ognjanovic S, Antic J, Pekmezovic T, et al. The association ofglucocorticoid receptor polymorphism with metabolic outcomesin menopausal women with adrenal incidentalomas. Maturitas.2021;151:15-21.
11. Vinolas H, Grouthier V, Mehsen-Cetre N, et al. Assessment of vertebralmicroarchitecture in overt and mild Cushing’s syndrome usingtrabecular bone score. Clin Endocrin.2018;89(2):148-154.
12. Hong SH, Choi KM. Sarcopenic obesity, insulin resistance, and theirimplications in cardiovascular and metabolic consequences. Int J MolSci. 2020;21(2):494.
13. Wong SK, Chin KY, Suhaimi FH, Ahmad F, Ima-Nirwana S. Therelationship between metabolic syndrome and osteoporosis: a review.Nutrients. 2016;8(6):347.
14. Wong SK, Chin KY, Suhaimi FH, Ahmad F, Jamil NA, Ima-Nirwana S.Osteoporosis is associated with metabolic syndrome induced by high-carbohydrate high-fat diet in a rat model. Biomed & Pharmacother.2018;98:191-200.
15. Lin HH, Huang CY, Hwang LC. Association between metabolicsyndrome and osteoporosis in Taiwanese middle-aged and elderlyparticipants. Archi Osteop. 2018;13(1):1-7.
16. Kim JH, Kwak MK, Ahn SH, et al. Alteration in skeletal muscle mass inwomen with subclinical hypercortisolism. Endocrine. 2018;61:134-143.
17. Kwak MK, Lee SE, Cho YY, et al. The differential effect ofexcess aldosterone on skeletal muscle mass by sex. FrontEndocrino.2019;10:195.
18. Moraes AB, Cavalari EMR, de Paula MP, et al. Evaluation of bodycomposition using dual-energy X-ray absorptiometry in patientswith non-functioning adrenal incidentalomas and an intermediatephenotype: is there an association with metabolic syndrome? JEndocrinol Invest. 2019;42(7):797-807.